Antengene Acquires Global Rights to AstraZeneca Cancer Candidate
publication date: Nov 7, 2019
Antengene, a Shanghai novel drug biopharma, has in-licensed global rights to a novel cancer treatment from AstraZeneca. The company said AstraZeneca has filed an open IND application for AZD0364, a selective small molecule ERK1/2 inhibitor, in the US for multiple solid tumor cancers. ERK is a key component of the Ras-Raf-MEK-ERK (RAS/MAPK) pathway, which promotes tumor cell growth and survival. Antengene expects the candidate will be effective as a monotherapy and in combination with other of its portfolio drugs. Details of the agreement were not disclosed. More details....
Stock Symbol: (NYSE: AZN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.